Sfoglia per AUTORE
MUSTO P
Collezione ASL Biella

  

Items : 14

End of induction [(18)F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial. in European journal of nuclear medicine and molecular imaging / Eur J Nucl Med Mol Imaging. 2024 May 25. doi: 10.1007/s00259-024-06765-z.

2024
ASL Biella
AOU Alessandria

Pennese E; Perrone T; Liberati AM; Ibatici A; Stefani PM; Vitolo U; Usai SV; Falcinelli F; Gini G; Roti G; Galimberti S; Musto P; Mannina D; Conconi A; Massaia M; Bari A; Arcari A; Califano C; Pavone V; Chiarenza A; Bolis SAM; Bianchi B; Tosi P; Musuraca G; Ladetto M; Barbieri E; Monaco L; Peano S; Franceschetto A; et alii...

Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naïve advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi. in Hematological oncology / Hematol Oncol. 2023 Oct;41(4):655-662. doi: 10.1002/hon.3184. Epub 2023 May 28.

2023
AO Cuneo
ASL Biella

Gini G; Federico M; Luminari S; Marcheselli L; Catellani H; Skrypets T; Stefani PM; Pastore D; Pennese E; Liberati AM; Ballerini F; Vitolo U; Usai SV; Capponi M; Galimberti S; Perrone T; Re F; Mannina D; Musto P; Conconi A; Bari A; Massaia M; Ghiggi C; Pulsoni A; Musuraca G; Califano C; Merli M; Manni M; Nizzoli ME; et alii...

Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts. in American journal of hematology / Am J Hematol. 2023 Aug;98(8):E204-E208. doi: 10.1002/ajh.26960. Epub 2023 May 24.

2023
ASL Città di Torino
ASL Torino 4
AO Cuneo
ASL Biella
AO Ordine Mauriziano
AOU Città della Salute di Torino
AOU Novara
AOU Alessandria

Della Porta MG; Naldi I; Santini V; Turrini M; Giordano L; Finelli C; Pasini P; Tosi P; Tanasi I; Selleri C; Frigeni M; Sancetta R; Norata M; Marchetti M; Grimaldi D; Fianchi L; Galimberti S; Ferrara F; Di Veroli A; Di Bona E; Occhini U; Rivoli G; Bono R; Calvisi A; Castelli A; Nicolino B; Leuzzi L; Molteni A; Guarini A; et alii...

A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. in Blood advances / Blood Adv. 2022 Jan 11;6(1):327-338. doi: 10.1182/bloodadvances.2021005691.

2022
ASL Torino 5
ASL Biella
AO Cuneo
AOU Città della Salute di Torino
ASL Cuneo 1
AOU Novara
AOU Alessandria

Ladetto M; Pilerci S; Pinto A; Ramadan S; Marchesi F; Cavo M; Musto P; Coviello E; Romano A; Passamonti F; Corradini P; Krampera M; Tosi P; Lanza F; Candoni A; Selleri C; Conconi A; Visani G; Vallisa D; Venditti A; Gambacorti-Passerini C; Rigacci L; La Barbera EO; Corso A; Armiento D; Cilloni D; Cardinali V; Galimberti S; Bocchia M; et alii...

Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anemia Due to Very Low, Low and Intermediate Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts, Who Had an Unsatisfactory Response to or Are Ineligible for Erythropoietin-Based Therapy: A Retrospective Multicenter Study By Fondazione Italiana Sindromi Mielodisplastiche (FiSiM ETS) in Blood

2022
ASL Biella
ASL Torino 4

Lanino L; Salutari P; Perego A; Fattizzo B; Riva M; Ubezio M; Musto P; Cilloni D; Oliva EN; Voso MT; Pelizzari AM; Poloni A; Capodanno I; Elena C; Fozza C; Pane F; Breccia M; De Gobbi M; Di Bassiano F; Barraco D; Crisà E; Ferrero D; Frairia C; Vaccarino A; Griguolo D; Paolini S; Quintini M; Sessa M; Turrini M; et alii...

Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice. in Cancer / Cancer. 2021 Jun 15;127(12):2015-2024. doi: 10.1002/cncr.33472. Epub 2021 Mar 19.

2021
ASL Torino 4
ASL Biella
AOU Città della Salute di Torino
AOU Novara

Angelucci E; Musto P; Abbadessa A; Capalbo SF; Castelli A; Oliva EN; Centurioni R; Alesiani F; Catarini M; Bigazzi C; Crugnola M; Zambello R; Fanin R; Cametti G; Freilone R; Cilloni D; Di Tucci AA; Danise P; Selleri C; Poloni A; Finelli C; Balleari E; Ferrero D; Allione B; Salvi F; Ceccarelli M; Guolo F; Miglino M; Crisà E; et alii...

Treatment of Relapsed/Refractory Waldenström Macroglobulinemia Patients: Final Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL) in Blood

2021
AOU Città della Salute di Torino
ASL Biella

Benevolo G; Ferrero S; Villivà N; Castiglione A; Monaco F; Boccomini C; Cabras MG; Califano C; Casula P; Cavallo F; Conconi A; Drandi D; Gaidano G; Gregorini AI; Felici S; Ferrante M; Mannina D; Molinari AL; Musto P; Musuraca G; Merli M; Sartori R; Tani M; Varettoni M; Vitolo U; Orsucci L;

Impact of Immunochemotherapy with R-Bendamustine or R-CHOP in the Post-Induction Management of Treatment Naïve Advanced Stage Follicular Lymphoma Patients: A Subset Analysis of the FOLL12 Trial By the Fondazione Italiana Linfomi (FIL) in Blood

2021
AOU Città della Salute di Torino
ASL Biella

Luminari S; Nizzoli ME; Chiarenza A; Mannina D; Tucci A; Boccomini C; Farina L; Olivieri J; Marcheselli L; Ferrero S; Arcaini L; Pulsoni A; Musuraca G; Califano C; Merli M; Bari A; Conconi A; Re F; Balzarotti M; Ladetto M; Patti C; Pinto A; Cabras MG; Musto P; Gini G; Arcari A; Manni M; Versari A; Federico M; et alii...

SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience. in HemaSphere / Hemasphere. 2020 Sep 23;4(5):e483. doi: 10.1097/HS9.0000000000000483. eCollection 2020 Oct.

2020
ASL Torino 5
ASL Biella
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Città della Salute di Torino
ASL Città di Torino
ASL Torino 4
AOU Alessandria
AOU Novara

Santini V; Tafuri A; Selleri C; Rivellini F; Secchi R; Sciumé M; Sarlo C; Riva M; Poloni A; Pilo F; Pelizzari A; Palumbo GA; Musto P; Oliva E; Messa E; Niscola P; Molteni A; Mancini S; Frattini F; Gaidano V; Guaragna G; Latagliata R; Gumenyuk S; Finelli C; Giai V; Fianchi L; Filì C; Ferrara IL; Fava C; et alii...

Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. in The Lancet. Haematology / Lancet Haematol. 2020 Oct;7(10):e737-e745. doi: 10.1016/S2352-3026(20)30251-9. Epub 2020 Aug 13.

2020
AOU Alessandria
ASL Biella
AOU Città della Salute di Torino
ASL Torino 5
AOU Novara

Grossi PA; Corradini P; Pagano L; Corrao G; Bertù L; Franchi M; Visco C; Rigacci L; Armiento D; Pane F; Oberti M; Zappasodi P; Galieni P; Fava C; Candoni A; Venditti A; Pinto A; Marchesi F; Musto P; Federici AB; Olivieri A; Gentile M; Bocchia M; Selleri C; Ortu La Barbera E; Ferrandina C; Di Renzo N; Luppi M; Scattolin AM; et alii...

Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study. in Blood cancer journal / Blood Cancer J. 2020 May 18;10(5):58. doi: 10.1038/s41408-020-0326-1.

2020
ASL Biella
ASL Asti
AOU Città della Salute di Torino
ASL Vercelli
AO Cuneo
AOU Alessandria

Sonneveld P; Boccadoro M; Larocca A; Musto P; Romano A; Ria R; Giuliani N; Offidani M; Liberati AM; Marchetti M; Mosca-Siez ML; de Fabritiis P; Ballanti S; Monaco F; Gobbi M; Cellini C; Grasso M; Ronconi S; Pescosta N; Petrucci MT; Capra A; Zambello R; Mina R; Di Lullo G; Belotti A;

Clinical and molecular results of the phase II BRB (bendamustine, rituximab and bortezomib) trial of the fondazione italiana linfomi (FIL) for relapsed/refractory waldenström macroglobulinemia patients in Blood

2018
ASL Biella
AOU Città della Salute di Torino

Benevolo G; Ferrero S; Andriani A; Castiglione A; Baraldi A; Boccomini C; Cabras MG; Califano C; Cavallo F; Conconi A; Curreli L; Drandi D; Gaidano G; Felici S; Ferrante M; Mannina D; Merli M; Molinari AL; Musto P; Musuraca G; Rossi FG; Sartori R; Tani M; Varettoni M; Vitolo U; Orsucci L;

Myelodysplastic syndromes with hypocellular marrow: Clinical characteristics and evaluation of outcome in HemaSphere

2018
ASL Biella
ASL Città di Torino
ASL Asti
ASL Torino 4
ASL Torino 5
AO Cuneo
AOU Città della Salute di Torino
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Alessandria
ASL Novara

Santini V; Gioia D; Masiera E; Poloni A; Ferrero D; Fragasso A; Finelli C; Salvi F; Gaidano G; Oliva EN; Catarini M; Cametti G; Bonferroni M; Danise P; Tassara R; Allione B; Cilloni D; Castelli A; Centurioni R; Ciravegna G; Visani G; Musto P; Balleari E; Biale L; Capelli D; Frairia C; Galimberti S; Giaccone L; Macchi S; et alii...

Rate and causes of 5-azacytidine discontinuation and subsequent therapeutic options in 418 MDS patients from the Italian MDS registry of fondazione Italiana sindromi mielodisplastiche (FISM) in Haematologica

2017
ASL Biella
ASL Torino 5
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Mezzabotta M; Conconi AR; Cametti G; Freilone R; Calzamiglia T; Cavaliere M; Gaidano V; Cilloni D; Danise P; Selleri C; Aguzzi C; Finelli C; Poloni A; Allione B; Di Tucci AA; Miglino M; Balleari E; Monagheddu C; Ceccarelli M; Gioia D; Clavio M; Santini V; Gaidano G; Pane F; Angelucci E; Levis A; Goretti R; Musto P;